![]() |
||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
||
![]() |
![]() |
![]() |
By studying proteins in more detail new insights into the precise nature, diagnostic value, and quality of many biomarkers can be obtained. Diagnostic assays that target IBI-identified protein variants can improve accuracy and reliability. In some cases PTM's may indicate a predilection for disease and can be used to stratify patients in clinical trials for improved outcomes. Patient safety can be enhanced by monitoring a broad range of indicators in parallel. Monitoring structural changes of protein therapeutics as they occur in vivo provides a more complete pharmacokinetic profile and avoids costly complications.
|
![]() |
![]() |
![]() |
![]() |
|||
![]() |
||||||||||
![]() |
||||||||||
Home | Sitemap | Directions | Literature © Copyright 2004 by Intrinsic Bioprobes, Inc. All Rights Reserved.
|